---
layout: post
title: "Prescription Drug User Fee Act VII; Independent Assessment of Communication Through Product Quality Information Requests During Application Review; Final Report; Availability; Reopening of Comment Period"
date: 2026-02-04 21:48:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-14684
original_published: 2025-08-04 00:00:00 +0000
significance: 8.00
---

# Prescription Drug User Fee Act VII; Independent Assessment of Communication Through Product Quality Information Requests During Application Review; Final Report; Availability; Reopening of Comment Period

**Published:** February 04, 2026 21:48 UTC
**Source:** Federal Register
**Original Published:** August 04, 2025 00:00 UTC
**Document Number:** 2025-14684

## Summary

The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the notice of availability entitled "Prescription Drug User Fee Act VII; Independent Assessment of Communication Through Product Quality Information Requests During Application Review; Final Report; Availability; Request for Comments" that appeared in the Federal Register of May 9, 2025. In the notice of availability, FDA requested comments on the final assessment report. The Agency is taking this action in response to a request to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/08/04/2025-14684/prescription-drug-user-fee-act-vii-independent-assessment-of-communication-through-product-quality)
- API: https://www.federalregister.gov/api/v1/documents/2025-14684

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
